GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » Deferred Policy Acquisition Costs

Titan Pharmaceuticals (FRA:TN70) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Titan Pharmaceuticals (FRA:TN70) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.